Craig-Hallum analyst Per Ostlund assigned a Buy rating to the stock today. The company’s shares closed yesterday at $2.11. According to ...
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback